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This special issue collects original research, reviews,scientific, and regulatory perspectives focusing on bio-
markers and surrogate endpoints in ophthalmic clinical
research.
Biomarkers and surrogate endpoints provide an essential set
of tools needed to translate scientific concepts into diagnostic
and therapeutic approaches and technologies. These tools have
significant potential for accelerating basic science, drug
discovery, medical product development, and for improving
clinical care.1
The first essential effort to improve the use of biomarkers
and surrogate endpoints should aim to get effective and
unambiguous communication. For this reason, since 2015 the
FDA-NIH Joint Leadership Council developed the BEST
(Biomarkers, EndpointS, and other Tools) glossary.2
In order to improve communication and understanding of
the conceptual framework, we felt that it would be important
to share with the readership of this special issue some contents
of the BEST Resource.
The currently accepted definition of the term biomarker is
‘‘a defined characteristic that is measured as an indicator of
normal biological processes, pathogenic processes, or respons-
es to an exposure or intervention, including therapeutic
interventions. [. . .] A biomarker is not an assessment of how
an individual feels, functions, or survives.’’2 Categories of
biomarkers are summarized in the Table.
Another central concept is the endpoints’ surrogacy. A
surrogate endpoint is defined as ‘‘an endpoint that is used in
clinical trials as a substitute for a direct measure of how a
patient feels, functions, or survives. A surrogate endpoint does
not measure the clinical benefit of primary interest in and of
itself, but rather is expected to predict that clinical benefit or
harm based on epidemiologic, therapeutic, pathophysiologic,
or other scientific evidence.’’2
Correlation with the clinical endpoint is a necessary but not
sufficient condition for surrogacy. A validated surrogate
endpoint must be ‘‘supported by a clear mechanistic rationale
and clinical data providing strong evidence that an effect on the
surrogate endpoint predicts a clinical benefit.’’2
As elegantly theorized in 1996 by Fleming and DeMets,3 in
the ideal setting for surrogacy, ‘‘the surrogate is in the only
causal pathway of the disease process, and the intervention’s
entire effect on the true clinical outcome is mediated through
its effect on the surrogate’’ (Fig. 1).
In the last few years, the role of biomarkers and surrogate
endpoints, together with the efforts needed for their validation
and the concerns related to their misuse, has become a hot
topic in ophthalmology (Fig. 2).
TABLE. Biomarkers’ Categories and Definitions Reported in the FDA-NIH BEST Resource2
Biomarker Category Definition Notes
Diagnostic biomarker A biomarker used to detect or confirm presence of a
disease or condition of interest or to identify individuals
with a subtype of the disease.
The limitations of a diagnostic biomarker test are related
to the clinical sensitivity and specificity of the
biomarker and to the analytical performance of the
measurement method.
Monitoring biomarker A biomarker measured serially for assessing status of a
disease or medical condition or for evidence of
exposure to (or effect of) a medical product or an
environmental agent.
The serial nature of the measurements focuses attention
on change in the biomarker’s value.
Pharmacodynamic/
Response biomarker
A biomarker used to show that a biological response has
occurred in an individual who has been exposed to a
medical product or an environmental agent.
Pharmacodynamic/response biomarkers do not necessarily
reflect the effect of an intervention on a future clinical
event (they may not be accepted surrogate endpoints).
Predictive biomarker A biomarker used to identify individuals who are more
likely than similar individuals without the biomarker to
experience a favorable or unfavorable effect from
exposure to a medical product or an environmental
agent.
Prognostic biomarkers and predictive biomarkers cannot
generally be distinguished when only patients who have
received a particular therapy are studied. To identify a
predictive biomarker, there generally should be a
comparison of a treatment to a control in patients with
and without the biomarker.
Prognostic biomarkers are often identified from
observational data and are regularly used to identify
patients more likely to have a particular outcome.
Prognostic biomarker A biomarker used to identify likelihood of a clinical event,
disease recurrence or progression in patients who have
the disease or medical condition of interest.
Safety biomarker A biomarker measured before or after an exposure to a
medical product or an environmental agent to indicate
the likelihood, presence, or extent of toxicity as an
adverse effect.
Ideally, a safety biomarker would signal developing toxicity
(e.g., drug induced organ injury) prior to clinical signs
and before any irreversible damage occurs.
Susceptibility/Risk
biomarker
A biomarker that indicates the potential for developing a
disease or medical condition in an individual who does
not currently have clinically apparent disease or the
medical condition.
Susceptibility/risk biomarkers may be detected many years
before the appearance of clinical signs and symptoms.
Susceptibility/risk biomarkers do not describe a
relationship to any specific treatment.
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This special issue is a great opportunity to take stock of this
important and complex topic. The invited and unsolicited
reviews provide precious information and novel updates on
scientific and regulatory issues. The original research report
new advances in biomarkers and surrogate endpoints devel-
opment, validation and usage in different areas of ophthalmic
clinical research and care.
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fundamental and anonymous work and all the researchers
who have contributed to this special issue.
We would also like to thank Thomas Yorio, Editor-in-Chief
of IOVS, for having shared our enthusiasm for this project
and for his invaluable guidance, and Marco Stoutamire, Gayle
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kind and constant support in managing the submissions.
We hope that this special issue will help to increase
awareness and to focus attention on the implications of this
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FIGURE 2. Biomarkers and surrogate endpoint publication volume in
ophthalmology, from PubMed abstract search performed on April 1,
2017.
FIGURE 1. Conceptual model of valid endpoint surrogacy.
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